These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Miners JO; Mackenzie PI; Knights KM Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925 [TBL] [Abstract][Full Text] [Related]
4. Glucuronidation of haloperidol by rat liver microsomes: involvement of family 2 UDP-glucuronosyltransferases. Narayanan R; LeDuc B; Williams DA Life Sci; 2004 Apr; 74(20):2527-39. PubMed ID: 15010263 [TBL] [Abstract][Full Text] [Related]
5. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Miners JO; Knights KM; Houston JB; Mackenzie PI Biochem Pharmacol; 2006 May; 71(11):1531-9. PubMed ID: 16455060 [TBL] [Abstract][Full Text] [Related]
6. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. Oda S; Fujiwara R; Kutsuno Y; Fukami T; Itoh T; Yokoi T; Nakajima M Drug Metab Dispos; 2015 Jun; 43(6):812-8. PubMed ID: 25834030 [TBL] [Abstract][Full Text] [Related]
7. UDP-glucuronic acid binds first and the aglycone substrate binds second to form a ternary complex in UGT1A9-catalyzed reactions, in both the presence and absence of bovine serum albumin. Manevski N; Yli-Kauhaluoma J; Finel M Drug Metab Dispos; 2012 Nov; 40(11):2192-203. PubMed ID: 22912433 [TBL] [Abstract][Full Text] [Related]
8. The effects of UDP-sugars, UDP and Mg Walia G; Smith AD; Riches Z; Collier AC; Coughtrie MWH Xenobiotica; 2018 Sep; 48(9):882-890. PubMed ID: 28868965 [TBL] [Abstract][Full Text] [Related]
9. A broad-spectrum substrate for the human UDP-glucuronosyltransferases and its use for investigating glucuronidation inhibitors. Zhou QH; Qin WW; Finel M; He QQ; Tu DZ; Wang CR; Ge GB Int J Biol Macromol; 2021 Jun; 180():252-261. PubMed ID: 33741369 [TBL] [Abstract][Full Text] [Related]
10. Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine. Shiraga T; Yajima K; Suzuki K; Suzuki K; Hashimoto T; Iwatsubo T; Miyashita A; Usui T Drug Metab Dispos; 2012 Feb; 40(2):276-82. PubMed ID: 22031623 [TBL] [Abstract][Full Text] [Related]
11. Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies. Donato MT; Montero S; Castell JV; Gómez-Lechón MJ; Lahoz A Anal Bioanal Chem; 2010 Mar; 396(6):2251-63. PubMed ID: 20145913 [TBL] [Abstract][Full Text] [Related]
12. The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs. Uchaipichat V; Suthisisang C; Miners JO Drug Metab Dispos; 2013 Jun; 41(6):1273-84. PubMed ID: 23554428 [TBL] [Abstract][Full Text] [Related]
13. Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Al Saabi A; Allorge D; Sauvage FL; Tournel G; Gaulier JM; Marquet P; Picard N Drug Metab Dispos; 2013 Mar; 41(3):568-74. PubMed ID: 23230132 [TBL] [Abstract][Full Text] [Related]
14. Design and optimization of the cocktail assay for rapid assessment of the activity of UGT enzymes in human and rat liver microsomes. Chen A; Zhou X; Cheng Y; Tang S; Liu M; Wang X Toxicol Lett; 2018 Oct; 295():379-389. PubMed ID: 30036684 [TBL] [Abstract][Full Text] [Related]
15. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity. Mutlib AE; Goosen TC; Bauman JN; Williams JA; Kulkarni S; Kostrubsky S Chem Res Toxicol; 2006 May; 19(5):701-9. PubMed ID: 16696573 [TBL] [Abstract][Full Text] [Related]
16. Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Engtrakul JJ; Foti RS; Strelevitz TJ; Fisher MB Drug Metab Dispos; 2005 Nov; 33(11):1621-7. PubMed ID: 16049128 [TBL] [Abstract][Full Text] [Related]
17. Everolimus-inhibited multiple isoforms of UDP-glucuronosyltransferases (UGTs). Du Z; Wang G; Cao YF; Hu CM; Yang K; Liu YZ; Zhang CZ; Zhang WH; Zhu ZT; Sun HZ; Sun XY; Hong M; Fang ZZ Xenobiotica; 2018 May; 48(5):452-458. PubMed ID: 28548030 [TBL] [Abstract][Full Text] [Related]
18. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by darolutamide: Prediction of in vivo drug-drug interactions. Xiao S; Yin H; Lv X; Wang Z; Jiang L; Xia Y; Liu Y Chem Biol Interact; 2024 Nov; 403():111246. PubMed ID: 39278459 [TBL] [Abstract][Full Text] [Related]
20. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform. Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]